Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of CP1050 in Healthy Subjects
NCT03468413Phase 1Unknown
- Sponsor
- Curadim Pharma
- Start
- Feb 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CP1050 in multiple sclerosis (MS) and autoimmune diseases (2 arms), sponsored by Curadim Pharma. Primary endpoints: Incidence and severity of any drug-related adverse events up to 21 days, Number of subjects with abnormal vital signs up to 21 days and 6 more. Status: unknown.
02
Drugs
CP1050
03
Conditions
multiple sclerosis (MS)autoimmune diseases
Beyond the preview
Go deeper on NCT03468413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03468413.